This startup is developing a sublingual strip medication designed to rapidly neutralize drugs used in sexual assault. The strip provides a convenient and fast-acting solution for individuals to protect themselves against drug-facilitated sexual assault.
Funding
Funding not disclosed
Founders
Product
Problem
Drug-facilitated sexual assault (DFSA) is a pervasive issue with limited options for immediate self-intervention when an individual suspects they have been drugged. Current responses often rely on emergency medical services, which may not be readily accessible or timely. There is a need for a discreet and rapidly acting solution that can be self-administered.
Solution
Mithradote Bio is developing M-101, a novel sublingual pan-antidote designed to counteract the effects of common "date-rape" drugs, including benzodiazepines, "Z drugs," and other GABA agonists. The medication is formulated as a sublingual strip for rapid absorption and ease of use. This allows for quick self-administration, potentially mitigating the effects of ingested substances. M-101 aims to provide a readily available option for individuals to take control of their situation in suspected DFSA scenarios.
Target Audience
The primary target audience includes individuals concerned about potential exposure to drug-facilitated sexual assault, as well as advocacy groups and healthcare providers focused on sexual assault prevention.
Features
- Sublingual strip formulation for rapid absorption and fast action.
- Designed to neutralize a spectrum of GABA agonists, including benzodiazepines and "Z drugs".
- Convenient and discreet packaging for easy portability.
- Self-administered, allowing for immediate response in suspected DFSA situations.